Related Experiment Video
Updated: Apr 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Comparative analysis of manufacturability and binding of various bispecific antibody architectures
Juan Carlos Rivera-Castro1, Octavio T Ramírez1, Laura A Palomares1
1Departamento de Medicina Molecular y Bioprocesos. Instituto de Biotecnología, Universidad Nacional Autónoma de México, Ave. Universidad 2001, Cuernavaca, Morelos 62210, Mexico.
Abstract:
Bispecific monoclonal antibodies (BsAbs) enable novel therapeutic mechanisms with multiple binding specificities, but their architecture can influence manufacturability and function. We compared the production of five formats of a BsAb recognizing a viral epitope with an added function through binding to the transferrin receptor (TfR) for blood-brain barrier passage. They had symmetric and asymmetric architectures, with additional binding domains fused to either the heavy or light chains, and a dual-variable domain immunoglobulin (DVD). We characterized growth kinetics, productivity, downstream recovery, product related variants and in vitro binding to Zika virus and TfR. BsAb architecture had a pronounced impact on culture performance. The formats involving light-chain modification or asymmetric assembly produced here resulted in reduced cell culture performance, including lower growth and viability, and up to 70% lower productivity, compared to the parental antibody. In contrast, symmetric BsAbs with C-terminal single chain variable fragment (scFv) fusion to the heavy chain maintained growth, productivity, and purification performance comparable to the parental IgG and achieved high purity after protein A purification (> 95%). Asymmetric BsAb production resulted in imbalanced chain expression and the formation of homodimeric and half-antibody byproducts, reducing purity after protein A purification to around 68%. Binding analysis using ELISA demonstrated that modifications affecting the Fab region modified apparent binding to Zika virus, whereas fusion of scFv domains to the heavy chain distal to the Fab preserved viral recognition. Apparent binding to TfR depended on BsAb valency and configuration, with bivalent heavy-chain scFv formats showing stronger apparent binding than monovalent formats. These results show that, within the architectures evaluated here, bispecific antibody architecture determines manufacturability, product quality, and binding. The results provide guidance for selecting BsAb formats that balance functional requirements with scalable production.
Related Concept Videos
The Equilibrium Binding Constant and Binding Strength
Drug Products: Biologics, Biosimilars and Interchangeables
Affinity and Avidity
Ligand Binding and Linkage
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

